Hosted on MSN1mon
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's
On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) said it received the final full data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary ...
CRN29d
Cognizant Gives Its Neuro AI Multi-Agent Capabilities For Better Decision-Making
'Neuro AI is our flagship AI platform,' Hodjat tells CRN. ‘We use it to develop decision-making use cases for our clients. Now we've made it agent-based. It’s a multi-agent-based system with ...
Business Wire1mon
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq ... today announced that it has received the final full data set from its multiple ascending dose clinical trial for AL001 treatment of ...